Nasdaq GlobeNewswire

OmniComm Systems Signs First TrialMaster® Customer in China

Del

Shanghai HEP Pharma Selects TrialMaster EDC to Conduct Hepatitis B Study

 

FORT LAUDERDALE, Fla., April 10, 2018 (GLOBE NEWSWIRE) -- Shanghai HEP Pharma Co. LTD, a research and development company focused on developing innovative drugs for hepatitis B, has signed a new agreement with OmniComm Systems, Inc. (OTCQX:OMCM), a leading global provider of clinical data management technology. Under the agreement, Shanghai HEP Pharma will use OmniComm's TrialMaster EDC technology for a randomized Phase II/Phase III hepatitis B study.  

The agreement represents OmniComm's first TrialMaster deal in China. More than two years ago, OmniComm established a goal of developing a presence in the Chinese market, and to-date the company's performance in that sector has met expectations. The expanded footprint in the Asia-Pacific region includes OmniComm's first contract for TrialMaster® in Japan, along with 13 TrialOne® agreements in China.                                                                                   

As a system that is compliant with global industry standards, TrialMaster allows user organizations to ensure the quality and integrity of the data collected and managed during the entire study. TrialMaster also enables users to comply with the Chinese FDA's new regulation and approval process for new drug development in China. TrialMaster's ability to facilitate users' compliance with CFDA's regulations aimed at harmonizing local practices to global standards was also a key factor.

"From our research and development pipeline, we have developed this hepatitis B drug from the concept stage," said Dr. Hongli Liu, CEO of Shanghai HEP Pharma. "This hepatitis B drug is a critical product for us, and we wanted to select a high quality and global standard EDC system to ensure our study is well managed. We had excellent experience using OmniComm's Phase I system, Promasys®, which naturally led to TrialMaster, OmniComm's Phase II/III EDC system. We look forward to working with OmniComm's team on study build and are confident to hit First Patient In date on time."

"We are very excited about our first deployment of TrialMaster in China, and it is with a highly innovative biotechnology company," said Kuno van der Post, Ph.D., chief commercial officer, OmniComm Systems. "We are delighted that we were selected in a highly competitive evaluation."

About OmniComm Systems, Inc. 
OmniComm provides comprehensive solutions for clinical research with an extensive global experience from more than 6,000 clinical trials. For more information, visit www.omnicomm.com.

Contact Info
Kuno van der Post
OmniComm Systems, Inc. 
+1.954.473.1254
KvanderPost@omnicomm.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: OmniComm Systems Inc. via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

General Electric Company: Dividend Declaration10.12.2018 08:00Pressemelding

FAIRFIELD, Conn., Dec. 10, 2018 (GLOBE NEWSWIRE) -- GE Board of Directors Authorizes Regular Quarterly Dividend The Board of Directors of GE (NYSE: GE) today declared a $0.01 per share dividend on the outstanding common stock of the Company. The dividend is payable January 25, 2019 to shareowners of record at the close of business on December 20, 2018. The ex- dividend date is December 19, 2018. About GE GE (NYSE:GE) drives the world forward by tackling its biggest challenges. By combining world-class engineering with software and analytics, GE helps the world work more efficiently, reliably, and safely. For more than 125 years, GE has invented the future of industry, and today it leads new paradigms in additive manufacturing, materials science, and data analytics. GE people are global, diverse and dedicated, operating with the highest integrity and passion to fulfill GE's mission and deliver for our customers. www.ge.com GE's Investor Relations website at www.ge.com/investor and our c

Brookfield Completes Acquisition of Forest City Realty Trust7.12.2018 19:24Pressemelding

NEW YORK and CLEVELAND, Dec. 07, 2018 (GLOBE NEWSWIRE) -- Brookfield Asset Management Inc. (“Brookfield”) (NYSE: BAM) (TSX: BAM.A) (Euronext: BAMA) and Forest City Realty Trust, Inc. (“Forest City”) (NYSE: FCEA) today announced the completion of the acquisition of Forest City by a Brookfield real estate investment fund. The transaction was approved at a special meeting of Forest City’s stockholders held on November 15, 2018. Forest City’s diversified real estate portfolio is comprised of a number of iconic assets across major gateway U.S. cities. The portfolio, which features many natural synergies with Brookfield’s existing real estate operating business, includes 6.3 million square feet of high-quality office space, 2.3 million square feet of premier life sciences assets, 2.2 million square feet of retail space and 18,500 multifamily units. In addition, the portfolio features five large-scale development projects in the New York Metro area, San Francisco and Washington, DC. In connec

Oxford Immunotec Announces Regulatory Acceptance of T-Cell Select™ in China7.12.2018 15:00Pressemelding

OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 07, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced regulatory acceptance of the T-Cell Select kit by the China Food and Drug Administration (CFDA). The T-Cell Select kit was designed as an immune cell separation reagent kit to simplify workflow, improve throughput, and reduce hands-on time and labor costs in performing the T-SPOT®.TB test. With the T-Cell Select kit, blood samples collected in a single standard blood tube can be stored for up to 54 hours at room temperature before use, further extending the company’s unrivaled simplicity and logistics advantages for customers. For additional information, please visit: http://www.oxfordimmunotec.com/international/products-services/t-cell-select/. About Oxford Immunotec Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary assays for im

Colliers International Announces Leadership Change6.12.2018 22:05Pressemelding

Dylan Taylor tapped to lead Colliers Real Estate Services TORONTO, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Colliers International Group Inc. (NASDAQ and TSX: CIGI), a global leader in commercial real estate services and investment management, announced today that effective January 1, 2019, Dylan Taylor will become CEO of Colliers Real Estate Services focusing exclusively on the growth, operational effectiveness and client service opportunities in the Company’s rapidly growing real estate services segment. Jay Hennick, Global Chairman and CEO will continue to be responsible for overall strategy and execution across all the Company’s businesses including its recently established platform in investment management. “Dylan Taylor’s appointment to CEO of Colliers Real Estate Services recognizes his success in building our operations over the last nine years. He will continue to be the driving force behind our growth in real estate services globally and perhaps most importantly, delivering exceptio

H&R Block Selects eGain for AI-Powered Customer Engagement6.12.2018 19:30Pressemelding

Tax preparation giant will use eGain Virtual Assistant for on-demand help SUNNYVALE, Calif., Dec. 06, 2018 (GLOBE NEWSWIRE) -- eGain (NASDAQ: EGAN), the leading provider of cloud-based customer engagement solutions, today announced that tax preparation giant H&R Block (NYSE: HRB) has selected eGain Solve™ to automate service and sales interactions for taxpayers at scale. The solution will be used to power H&R Block’s new Ask a Tax Pro service, which was announced today. According to a 2018 Accenture global survey, 70 percent of taxpayers said they would use AI to improve the accuracy of tax filings. In the same survey, 40 percent of respondents reported making a filing error in the last 24 months. As the market leader in tax preparation services, H&R Block wanted to provide high-quality DIY and advisor-assisted experiences at scale using AI, Machine Learning and Virtual Assistance. H&R Block selected eGain based on the company’s connected and rich solution capabilities, domain expertis

Constellation Brands to Invest $100 Million in Women-Led Start-Ups by 20286.12.2018 15:00Pressemelding

Focus on Female Founders Program Provides Resources to Help Women Entrepreneurs Address Untapped Growth Opportunities in the Beverage Alcohol Space and Adjacent Categories VICTOR, N.Y., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ and STZ.B), a leading beverage alcohol company, announced today that Constellation Brands Ventures (CBV), the company’s corporate venture capital group, intends to invest $100 million in female-founded or female-led businesses in the beverage alcohol space and adjacent categories by 2028 through a new program, Focus on Female Founders. The company has completed its first investments in two specialty beverage companies: Austin Cocktails and Vivify Beverages. “Our Focus on Female Founders program reinforces our commitment to supporting the advancement of women within our company, within our industry, and in our local communities,” said Mallika Monteiro, chief growth officer, Constellation Brands. “This program is designed to make mean

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom